These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 27556178)

  • 1. Phase II organ-preservation trial: Concurrent cisplatin and radiotherapy for advanced laryngeal cancer after response to docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy.
    Popovtzer A; Burnstein H; Stemmer S; Limon D; Hili O; Bachar G; Sopov V; Feinmesser R; Groshar D; Shvero J
    Head Neck; 2017 Feb; 39(2):227-233. PubMed ID: 27556178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Could the Addition of Cetuximab to Conventional Radiation Therapy Improve Organ Preservation in Those Patients With Locally Advanced Larynx Cancer Who Respond to Induction Chemotherapy? An Organ Preservation Spanish Head and Neck Cancer Cooperative Group Phase 2 Study.
    Mesía R; Garcia-Saenz JA; Lozano A; Pastor M; Grau JJ; Martínez-Trufero J; Lambeaz J; Martínez-Galán J; Mel JR; González B; Vázquez S; Mañós M; Taberna M; Cirauqui B; Del Barco E; Casado E; Rubió-Casadevall J; Rodríguez-Jaráiz A; Cruz JJ;
    Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):473-480. PubMed ID: 28011050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term Results of a Multicenter Randomized Phase III Trial of Induction Chemotherapy With Cisplatin, 5-fluorouracil, ± Docetaxel for Larynx Preservation.
    Janoray G; Pointreau Y; Garaud P; Chapet S; Alfonsi M; Sire C; Jadaud E; Calais G
    J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26681800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TPF induction chemotherapy and concomitant irradiation with cisplatin and cetuximab in unresectable squamous cell carcinoma of the head and neck.
    Strojan P; Grašič Kuhar C; Žumer B; Kadivec M; Karner K; Fajdiga I; Jančar B; Gale N; Poljak M; Kocjan BJ; Zakotnik B
    Head Neck; 2014 Nov; 36(11):1555-61. PubMed ID: 24123552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis.
    Kim R; Hahn S; Shin J; Ock CY; Kim M; Keam B; Kim TM; Kim DW; Heo DS
    Cancer Res Treat; 2016 Jul; 48(3):907-16. PubMed ID: 26582394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction chemotherapy-based larynx preservation program for locally advanced hypopharyngeal cancer: oncologic and functional outcomes and prognostic factors.
    Bozec A; Benezery K; Ettaiche M; Chamorey E; Vandersteen C; Dassonville O; Poissonnet G; Riss JC; Hannoun-Lévi JM; Chand ME; Leysalle A; Saada E; Guigay J; Sudaka A; Demard F; Santini J; Peyrade F
    Eur Arch Otorhinolaryngol; 2016 Oct; 273(10):3299-306. PubMed ID: 26858198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential four-drug chemotherapy and intensity-modulated radiotherapy for larynx preservation in resectable advanced larynx and hypopharynx cancer: A pilot study.
    Su X; He C; Tang T; Chen W; Li Z; Chen Y; Yang A
    Am J Otolaryngol; 2017; 38(1):52-56. PubMed ID: 27825651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation.
    Posner MR; Norris CM; Wirth LJ; Shin DM; Cullen KJ; Winquist EW; Blajman CR; Mickiewicz EA; Frenette GP; Plinar LF; Cohen RB; Steinbrenner LM; Freue JM; Gorbunova VA; Tjulandin SA; Raez LE; Adkins DR; Tishler RB; Roessner MR; Haddad RI;
    Ann Oncol; 2009 May; 20(5):921-7. PubMed ID: 19179556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-01): A randomized phase II study.
    Driessen CM; de Boer JP; Gelderblom H; Rasch CR; de Jong MA; Verbist BM; Melchers WJ; Tesselaar ME; van der Graaf WT; Kaanders JH; van Herpen CM
    Eur J Cancer; 2016 Jan; 52():77-84. PubMed ID: 26655558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer.
    Forastiere AA; Zhang Q; Weber RS; Maor MH; Goepfert H; Pajak TF; Morrison W; Glisson B; Trotti A; Ridge JA; Thorstad W; Wagner H; Ensley JF; Cooper JS
    J Clin Oncol; 2013 Mar; 31(7):845-52. PubMed ID: 23182993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck.
    Komatsu M; Shiono O; Taguchi T; Sakuma Y; Nishimura G; Sano D; Sakuma N; Yabuki K; Arai Y; Takahashi M; Isitoya J; Oridate N
    Jpn J Clin Oncol; 2014 May; 44(5):416-21. PubMed ID: 24688084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up.
    Psyrri A; Kwong M; DiStasio S; Lekakis L; Kassar M; Sasaki C; Wilson LD; Haffty BG; Son YH; Ross DA; Weinberger PM; Chung GG; Zelterman D; Burtness BA; Cooper DL
    J Clin Oncol; 2004 Aug; 22(15):3061-9. PubMed ID: 15284256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction chemotherapy followed by cisplatin or cetuximab concomitant to radiotherapy for laryngeal/hypopharyngeal cancer: Long-term results of the TREMPLIN randomised GORTEC trial.
    Janoray G; Pointreau Y; Alfonsi M; Sire C; Geoffrois L; de Raucourt D; Bardet E; Calais MH; Garaud P; Calais G
    Eur J Cancer; 2020 Jul; 133():86-93. PubMed ID: 32454417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with cisplatin concurrent chemoradiotherapy for nonmetastatic Stage IV head-and-neck squamous cell carcinomas.
    Prestwich RJ; Öksüz DÇ; Dyker K; Coyle C; Şen M
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e237-43. PubMed ID: 21620580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment results of alternating chemoradiotherapy with early assessment for advanced laryngeal cancer: A multi-institutional phase II study.
    Nakata Y; Ijichi K; Hanai N; Nishikawa D; Suzuki H; Hirakawa H; Kodaira T; Fujimoto Y; Fujii T; Miyazaki T; Shimizu T; Hasegawa Y
    Auris Nasus Larynx; 2017 Feb; 44(1):104-110. PubMed ID: 27435048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Organ preservation and treatment toxicity with induction chemotherapy followed by radiation therapy or chemoradiation for advanced laryngeal cancer.
    Guadagnolo BA; Haddad RI; Posner MR; Weeks L; Wirth LJ; Norris CM; Sullivan CA; Goguen L; Busse PM; Tishler R
    Am J Clin Oncol; 2005 Aug; 28(4):371-8. PubMed ID: 16062079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): A meta-analysis of randomized trials.
    Budach W; Bölke E; Kammers K; Gerber PA; Orth K; Gripp S; Matuschek C
    Radiother Oncol; 2016 Feb; 118(2):238-43. PubMed ID: 26589131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 2 study of docetaxel, cisplatin, and concurrent radiation for technically resectable stage III-IV squamous cell carcinoma of the head and neck.
    Inohara H; Takenaka Y; Yoshii T; Nakahara S; Yamamoto Y; Tomiyama Y; Seo Y; Isohashi F; Suzuki O; Yoshioka Y; Sumida I; Ogawa K
    Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):934-41. PubMed ID: 25832686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy-final results of the larynx organ preservation trial DeLOS-II.
    Dietz A; Wichmann G; Kuhnt T; Pfreundner L; Hagen R; Scheich M; Kölbl O; Hautmann MG; Strutz J; Schreiber F; Bockmühl U; Schilling V; Feyer P; de Wit M; Maschmeyer G; Jungehülsing M; Schroeder U; Wollenberg B; Sittel C; Münter M; Lenarz T; Klussmann JP; Guntinas-Lichius O; Rudack C; Eich HT; Foerg T; Preyer S; Westhofen M; Welkoborsky HJ; Esser D; Thurnher D; Remmert S; Sudhoff H; Görner M; Bünzel J; Budach V; Held S; Knödler M; Lordick F; Wiegand S; Vogel K; Boehm A; Flentje M; Keilholz U
    Ann Oncol; 2018 Oct; 29(10):2105-2114. PubMed ID: 30412221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of incorporating cetuximab into docetaxel/cisplatin/fluorouracil induction chemotherapy and chemoradiotherapy for inoperable squamous cell carcinoma of the oral cavity: A phase II study.
    Chang PM; Lu HJ; Wang LW; Tai SK; Chen MH; Chu PY; Yang MH
    Head Neck; 2017 Jul; 39(7):1333-1342. PubMed ID: 28370774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.